ArticleMetabolic brain disease2016
Acid glycosaminoglycan (aGAG) excretion is increased in children with autism spectrum disorder, and it can be controlled by diet.
Article in Metabolic brain disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- A synthetic HS structure selectively impairs the morphology and function of excitatory synapse by disrupting neurexin1 interactions.Glycobiology · 2025Article
- Trace Element Changes in the Plasma of Autism Spectrum Disorder Children and the Positive Correlation Between Chromium and Vanadium.Biological trace element research · 2022Article
- Effect of stigma maydis polysaccharide on the gut microbiota and transcriptome of VPA induced autism model rats.Frontiers in microbiology · 2022Article
- Decreased phenol sulfotransferase activities associated with hyperserotonemia in autism spectrum disorders.Translational psychiatry · 2021Article
- High Levels of Glycosaminoglycans in the Urines of Children with Attention-Deficit/Hyperactivity Disorder (ADHD).Journal of molecular neuroscience : MN · 2020Article
- Oxidative Stress in Autism Spectrum Disorder.Molecular neurobiology · 2020Review
- Diagnostic and Severity-Tracking Biomarkers for Autism Spectrum Disorder.Journal of molecular neuroscience : MN · 2018Review
- Relationship between absolute and relative ratios of glutamate, glutamine and GABA and severity of autism spectrum disorder.Metabolic brain disease · 2018Article
- Relationship between selenium, lead, and mercury in red blood cells of Saudi autistic children.Metabolic brain disease · 2017Article
- Dietary adequacy of Egyptian children with autism spectrum disorder compared to healthy developing children.Metabolic brain disease · 2017Article
- Hair toxic and essential trace elements in children with autism spectrum disorder.Metabolic brain disease · 2017Article
- Altered urinary porphyrins and mercury exposure as biomarkers for autism severity in Egyptian children with autism spectrum disorder.Metabolic brain disease · 2016Observational
- Glycan susceptibility factors in autism spectrum disorders.Molecular aspects of medicine · 2016Review
- Evaluation of whole blood zinc and copper levels in children with autism spectrum disorder.Metabolic brain disease · 2016Article
- The levels of blood mercury and inflammatory-related neuropeptides in the serum are correlated in children with autism spectrum disorder.Metabolic brain disease · 2016Article
- The role of heparan sulfate deficiency in autistic phenotype: potential involvement of Slit/Robo/srGAPs-mediated dendritic spine formation.Neural development · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism research continues to receive considerable attention as the options for successful management are limited. The understanding of the autism spectrum disorder (ASD) etiology has now progressed to encompass genetic, epigenetic, neurological, hormonal, and environmental factors that affect outcomes for patients with ASD. Glycosaminoglycans (GAGs) are a family of linear, sulfated polysaccharides that are associated with central nervous system (CNS) development, maintenance, and disorders. Proteoglycans (PG) regulate diverse functions in the central nervous system. Heparan sulfate (HS) and chondroitin sulfate (CS) are two major GAGs present in the PGs of the CNS. As neuroscience advances, biochemical treatments to correct brain chemistry become better defined. Nutrient therapy can be very potent and has minimal to no side effects, since no molecules foreign to the body are needed. Given GAGs are involved in several neurological functions, and that its level can be somewhat modulated by the diet, the present study aimed to evaluate the role of GAGs levels in ASD symptoms. Both tGAG and its different fractions were evaluated in the urine of ASD and healthy control childrens. As levels differed between groups, a second trial was conduted evaluating if diet could reduce tGAG levels and if this in turn decrease ASD symptoms. The present study found that tGAG concentration was significantly higher in the urine of children with ASD compared to healthy control children and this was also evident in all GAG fractions. Within groups (controls and ASD), no gender differences in GAG excretion were found. The use of a 90 days elimination diet (casein-free, special carbohydrates, multivitamin/mineral supplement), had major effects in reducing urinary tGAG excretion in children with ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.